FAQ: Quantum BioPharma's Warrant Expiration and CVR Distribution Details
Summary
Quantum BioPharma announced the expiration of final hedge fund warrants from a 2020 financing and confirmed October 27, 2025 as the record date for distributing contingent value rights to Class B shareholders, which could entitle them to a share of potential litigation proceeds.
What is the main announcement from Quantum BioPharma?
Quantum BioPharma announced the expiration of the final tranche of warrants issued to hedge funds and investment funds from a 2020 financing, and confirmed October 27, 2025 as the record date for distributing contingent value rights (CVRs) to Class B shareholders.
What are the contingent value rights (CVRs) and what do they entitle shareholders to?
The CVRs entitle Class B Subordinate Voting Shareholders to a potential pro rata share of 10%-50% of any net proceeds from Quantum BioPharma’s $700 million litigation against CIBC World Markets, RBC Dominion Securities, and others, distributed on a one-for-one basis.
When is the record date for the CVR distribution?
The record date for the CVR distribution is October 27, 2025, as confirmed by the company in this announcement.
What was the significance of the warrant expiration?
The expiration of 53,147 warrants (originally 3,454,543 pre-reverse-split warrants) marks the final tranche of warrants issued to hedge funds and investment funds as part of a 2020 financing, completing this financial obligation.
What is Quantum BioPharma’s primary business focus?
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for treating challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different development stages.
What is Lucid-MS and why is it important to Quantum BioPharma?
Lucid-MS is Quantum BioPharma’s lead compound through its subsidiary Lucid Psycheceuticals Inc., a patented new chemical entity shown to prevent and reverse myelin degradation (the underlying mechanism of multiple sclerosis) in preclinical models.
What is Quantum BioPharma’s relationship with Unbuzzd Wellness Inc.?
Quantum BioPharma invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining 20.11% ownership (as of March 31, 2025) and receiving 7% royalty payments on sales until payments total $250 million, then 3% in perpetuity, while keeping 100% rights for pharmaceutical and medical uses.
Where can investors find more information about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM, and the full press release can be viewed at https://ibn.fm/g52XC.
What other business activities does Quantum BioPharma engage in?
Through its wholly owned subsidiary FSD Strategic Investments Inc., Quantum BioPharma maintains a portfolio of strategic investments representing loans secured by residential or commercial property.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 259251